The proprietary technology by SkinBioTherapeutics is derived from probiotic bacteria
SkinBioTherapeutics, the skin health company based in Manchester (UK), has announced that results of its first human study show the efficacy of its proprietary technology.
The independent study concluded that SkinBiotix, a product derived from probiotic bacteria, is safe and well tolerated and has efficacy in certain age groups.
Moreover, the research demonstrated that the change in skin hydration and water loss are in line with expectations from laboratory studies that have shown that SkinBiotix increases the levels of proteins within the skin that are crucial for a healthy barrier.
The increase in skin hydration in the younger group at day 15 may reflect the ability of younger skin to respond to the SkinBiotix faster than older skin.
The skin, the body’s largest organ, is colonised by a diverse range of microorganisms, which has to be managed for long-term good health.
SkinBioTherapeutics’ patented technology is developing a range of products based on lysates (extracts of probiotic bacteria) that will help keep the skin healthier and treat certain conditions.
The study was primarily undertaken to show the effects of SkinBiotix on the barrier of healthy skin.
An important secondary endpoint was to show that the technology is safe and well tolerated in a large group of people (129) using it twice a day for an extended period of time (29 days).
The study design involved three groups:
Measures of the barrier were then performed in all groups at 15 days and 29 days. The primary measures were Corneometry – a measure of how hydrated the skin is, and Transepidermal water loss (“TEWL”) -a measure of water loss from the skin. A change to the barrier might be expected to be reflected in an increase in skin hydration or a reduction in TEWL. Some additional measurements of skin elasticity were also taken.
The data showed:
These positive results follow the announcement, made in February, which detailed the £1.5 million investment SkinBioTherapeutics raised from its original investor Seneca.
This investment will enable the company to further explore opportunities for its existing technology and support new areas of development.
Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “We are really pleased by these data. To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix® to make it more suitable for different age groups.
"It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema”.